Centro Paulista de Investigação Clínica - CEPIC

Centro Paulista de Investigação Clínica - CEPIC
R. Moreira e Costa, 342 - Ipiranga, São Paulo - SP, 04266-010
Select an option
Our team
Medical staff
Andrea Lomonte
Agatha Sálvio Fernandes
Tiago Freitas
Vanessa Padua
Mariana Ribeiro
Nathaly Silva
Flora Marcolino
Henrique Alves Cusin
Vitorya Jennifer Melo
Nathalia Fossaluza Gonçalves
Nathalia Martins Beiro
Giovanna Tamarindo da Silveira
Open studies
Lupus
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus - APATURA - SanofiSee more
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus - TOPAZ-1 - BiogenSee more
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) - POETYK SLE-1 - Bristol-Myers SquibbSee more
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus - POETYK SLE-2 - Bristol-Myers SquibbSee more
A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy - AMETHYST - BiogenSee more
Cardiovascular disease
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels - REDEFINE 3 - Novo Nordisk A/SSee more
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Hypercholesterolemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Migraine
Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine - Eurofarma Laboratorios S.A.See more
Obesity
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels - REDEFINE 3 - Novo Nordisk A/SSee more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy